B-cell Non-Hodgkin Lymphoma
Conditions
Brief summary
This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of intravenous (IV) or subcutaneous (SC) mosunetuzumab in combination with polatuzumab vedotin in participants with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). It will consist of a dose finding portion followed by an expansion phase for second line or later (2L+) participants with relapsed or refractory (R/R) DLBCL and 2L+ R/R FL. In addition, subcutaneous mosunetuzumab in combination with polatuzumab vedotin will be evaluated in participants with at least 2 prior lines of systemic therapy (3L+) for the treatment of R/R mantle cell lymphoma (MCL) and in participants with 2L+ R/R DLBCL.
Interventions
Participants will receive intravenous (IV) mosunetuzumab.
Participants will receive subcutaneous (SC) mosunetuzumab.
DRUGPolatuzumab vedotin
Participants will receive IV polatuzumab vedotin.
DRUGTocilizumab
Participants will receive IV tocilizumab as needed.
DRUGRituximab
Participants will receive IV rituximab.
Sponsors
Hoffmann-La Roche
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * ECOG PS of 0, 1, or 2 * Histologically confirmed FL, DLBCL, or MCL * Must have received at least one prior systemic treatment regimen containing an anti-CD20-directed therapy for DLBCL or FL * For MCL, participants must have received at least two prior systemic treatment regiments, which include 1) anti-CD20-directed therapy, 2) BTK inhibitor, and 3) anthracycline or bendamustine * Relapsed to prior regimen(s) after having a documented history of response (complete response \[CR\], CR unconfirmed \[CRu\], or partial response \[PR\]) of \>/= 6 months in duration from completion of regimen(s); or, refractory to any prior regimen, defined as no response to the prior therapy, or progression within 6 months of completion of the last dose of therapy * Measurable disease, defined as at least one bi-dimensionally measurable nodal lesion, defined as \> 1.5 cm in its longest dimension, or at least one bi-dimensionally measurable extranodal lesion, defined as \> 1.0 cm in its longest dimension * Adequate hematologic, renal, and hepatic function Key
Exclusion criteria
* Prior treatment with mosunetuzumab or other CD20-directed bispecific antibodies * Prior treatment with polatuzumab vedotin * Current \> Grade 1 peripheral neuropathy * Prior use of any monoclonal antibody, radioimmunoconjugate or antibody-drug conjugate (ADC) within 4 weeks before first dose of study treatment * Treatment with any chemotherapeutic agent, or treatment with any other anti-cancer agent (investigational or otherwise) within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to first dose of study treatment * Treatment with radiotherapy within 2 weeks prior to the first dose of study treatment * Autologous stem-cell transplantation (SCT) within 100 days prior to first study treatment administration * Prior treatment with chimeric antigen receptor T-cell (CAR-T) therapy within 30 days before first study treatment administration * Prior allogeneic SCT * Prior solid organ transplantation * Known or suspected history of hemophagocytic lymphohistiocytosis (HLH) * Patients with history of confirmed progressive multifocal leukoencephalopathy (PML) * Current or past history of central nervous system (CNS) lymphoma or CNS disease * History of autoimmune disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum Tolerated Dose (MTD) of Mosunetuzumab in Combination with Polatuzumab Vedotin | Cycle 1 to Cycle 2 (cycle length = 21 days) |
| Recommended Phase II Dose of Mosunetuzumab in Combination with Polatuzumab Vedotin | Cycle 1 to Cycle 2 (cycle length = 21 days) |
| Percentage of Participants with Adverse Events (AE) | Baseline through approximately 90 days after last study treatment |
| Best Objective Response Rate (ORR), Defined as CR or Partial Response (PR) at any Time, Based on PET-CT and/or CT Scan, as Determined by the Independent Review Committee (IRC) using Standard Criteria for NHL | Baseline up to approximately 60 months (assessed at screening and then every 3 months for the first year, then every 6 months until disease progression, start of new anti-cancer therapy, or withdrawal) |
Secondary
| Measure | Time frame |
|---|---|
| Duration of Response (DOR) as Determined by the Investigator and IRC Using Standard Criteria for NHL | From the first occurrence of a documented response to disease progression, relapse, or death from any cause, whichever occurs first (up to approximately 60 months) |
| Progression-Free Survival (PFS) as Determined by the Investigator and IRC Using Standard Criteria for NHL | From time of first study treatment to the first occurrence of disease progression, relapse, or death from any cause, whichever occurs first (up to approximately 60 months) |
| Event-Free Survival (EFS) as Determined by the Investigator and IRC Using Standard Criteria for NHL | From time of first study treatment to the first occurrence of disease progression, relapse, initiation of new anti-lymphoma treatment (NALT), or death from any cause, whichever occurs first (up to approximately 60 months) |
| Best ORR (CR or PR at any Time) Based on PET-CT and/or CT Scan, as Determined by the Investigator Using Standard Criteria for NHL | Baseline up to approximately 60 months (assessed at screening and then every 3 months for the first year, then every 6 months until disease progression, start of new anti-cancer therapy, or withdrawal) |
| Anti-Drug Antibodies (ADAs) to Mosunetuzumab | At pre-defined intervals from C1D1 through approximately 90 days after the last study treatment |
| ADAs to Polatuzumab Vedotin | At pre-defined intervals from C1D1 through approximately 90 days after the last study treatment |
| Mosunetuzumab Serum Concentration | At pre-defined intervals from C1D1 through approximately 90 days after the last study treatment |
| Overall Survival (OS) | From time of first study treatment to death from any cause (up to approximately 60 months) |
| Best CR Rate on Study Based on PET-CT, and/or CT Scan, as Determined by the Investigator and IRC Using Standard Criteria for NHL | Baseline up to approximately 60 months (assessed at screening and then every 3 months for the first year, then every 6 months until disease progression, start of new anti-cancer therapy, or withdrawal) |
| CR Rate at the Time of Primary Response Assessment (PRA) Based on PET-CT, as Determined by the Investigator and IRC Using Standard Criteria for NHL | Cycle 8 completion (participants receiving mosunetuzumab), or 5-7 weeks after Cycle 6 (polatuzumab+bendamustine+rituximab participants) (Cycle = 21 days) |
| ORR, Defined as CR or PR, at PRA Based on PET-CT as Determined by the Investigator and IRC Using Standard Criteria for NHL | Cycle 8 completion (participants receiving mosunetuzumab), or 5-7 weeks after Cycle 6 (polatuzumab+bendamustine+rituximab participants) (Cycle = 21 days) |
Countries
Belgium, Canada, Spain, United Kingdom, United States
Outcome results
None listed